TABLE 2.
Cardioprotective medication use and low-density lipoprotein cholesterol (LDL-C) level by risk category in hemodialysis patients*
| Risk category | ACEI/ARB | Beta- blocker | ASA | Statin | LDL-C >2.5 mmol/L |
|---|---|---|---|---|---|
| Cohort (n=185) | 24.9 | 31.9 | 37.8 | 45.4 | 29.2 |
| DM (n=66) | 27.3 | 29.7 | 39.1 | 51.6 | 35.1 |
| CAD (n=89) | 32.6 | 44.9 | 56.3 | 59.1 | 32.6 |
| CAD+/DM+ (n=38) | 31.6 | 39.5 | 50.0 | 52.6 | 40.5 |
| CAD+/DM− (n=51) | 33.3 | 49.0 | 61.2 | 64.0 | 26.5 |
*
Expressed as percentage. ACEI/ARB Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker; ASA Acetylsalicylic acid; CAD Coronary artery disease; CAD+ Established history of CAD; DM Diabetes mellitus; DM+ DM present; DM− DM absent